Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2011. The report serves as a notification of transactions involving a Person Discharging Managerial Responsibility (PDMR) in accordance with Disclosure Rule 3.1.4R(1)(a).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of insider trading activity rather than a financial performance report.
Material Changes
The material change disclosed is an increase in share ownership by a senior executive:
- Dr P J T Vallance purchased 6,347 Ordinary shares.
- Transaction Date: Friday, March 25, 2011.
- Price: £11.76 per share.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of the specific share purchase transaction.
Key Facts for Investor Verification
- Verify the total shareholding of Dr P J T Vallance following this purchase.
- Confirm the market price of GSK Ordinary shares on March 25, 2011, to contextualize the £11.76 purchase price.
- Review subsequent filings to determine if this transaction was part of a broader insider trading pattern or a one-off event.